Search results for "Fibril"

showing 10 items of 836 documents

Health-related quality of life, anxiety and depression up to 12 months post-stroke: Influence of sex, age, stroke severity and atrial fibrillation - …

2021

Abstract Background Stroke can negatively impact the health-related quality of life (HRQoL). Anxiety or depression after stroke have been associated with poorer HRQoL, higher mortality and greater dependence in activities of daily living. We aimed to analyze HRQoL, anxiety and depressive symptoms in patients with and without atrial fibrillation (AF) up to 12 months post-stroke. Methods Find-AFRANDOMISED was a prospective, randomized multicenter study, which included 398 patients ≥60 years with acute cerebral ischemia. HRQoL data were collected using the 3-level EuroQol-5D (EQ-5D-3L) and Stroke Impact Scale (SIS-16). Anxiety and depressive symptoms were measured using the Hospital Anxiety an…

Malemedicine.medical_specialtyTime FactorsAnxietyHospital Anxiety and Depression Scale03 medical and health sciences0302 clinical medicineSex FactorsQuality of lifeModified Rankin ScaleInternal medicineActivities of Daily LivingAtrial FibrillationmedicineHumanscardiovascular diseases030212 general & internal medicineLongitudinal StudiesProspective StudiesStrokeDepression (differential diagnoses)Agedbusiness.industryDepressionAge FactorsAtrial fibrillationmedicine.diseasehumanities3. Good healthClinical trialStrokePsychiatry and Mental healthClinical PsychologyQuality of LifeAnxietyFemalemedicine.symptombusiness030217 neurology & neurosurgeryJournal of psychosomatic research
researchProduct

Sudden cardiac death while wearing a Holter monitor

1991

The Holter tapes of 61 patients (46 men, mean age +/- standard deviation 65 +/- 11 years) with sudden cardiac death while being monitored were analyzed. Thirty-eight patients were known to have coronary artery disease, 5 had cardiomyopathy, and 7 had aortic valve disease. Etiology remained unknown in 11 patients. Mean New York Heart Association functional class was 2.5 +/- 0.7. Thirty patients had received antiarrhythmic drugs and 32 had received digitalis. Sudden death occurred at rest in 73%. In the hours before death, repetitive ventricular arrhythmias were found in 50 patients (82%), with atrial fibrillation in 34%. Patients with bradyarrhythmic death (18%) had less complex ventricular …

Malemedicine.medical_specialtyTime FactorsCardiomyopathyTorsades de pointes030204 cardiovascular system & hematologyVentricular tachycardiaSudden deathSudden cardiac deathDeath Sudden03 medical and health sciences0302 clinical medicineHeart RateTachycardiaInternal medicineAtrial FibrillationmedicineHumanscardiovascular diseases030212 general & internal medicineAgedmedicine.diagnostic_testbusiness.industryArrhythmias CardiacSignal Processing Computer-AssistedAtrial fibrillationmedicine.diseasePrimary ventricular fibrillationHeart Arrest3. Good healthAnesthesiaElectrocardiography Ambulatorycardiovascular systemCardiologyFemaleCardiology and Cardiovascular MedicinebusinessElectrocardiographyThe American Journal of Cardiology
researchProduct

Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups

2014

This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (<75), at or after age 75 (≥75), and the overall population (All) from a US Medicare payer perspective. Clinical event rates by age cohort with dabigatran or warfarin for safety-on-treatment and intent-to-treat populations were estimated from Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY). An economic model was adapted using these data to evaluate the impact of starting age on clinical and economic outcomes. Costs were obtained from Medicare p…

Malemedicine.medical_specialtyTime FactorsCost effectivenessCost-Benefit AnalysisMedicareAntithrombinsDrug Administration ScheduleDrug CostsDabigatranThromboembolismInternal medicineAtrial FibrillationmedicineHumansIn patientcardiovascular diseasesStrokeAgedbusiness.industryIncidenceFollow up studiesWarfarinSystemic embolismAtrial fibrillationPrognosismedicine.diseaseUnited StatesDabigatranbeta-AlanineCardiologyBenzimidazolesFemalebusinessCardiology and Cardiovascular MedicineFollow-Up Studiesmedicine.drugThe American Journal of Cardiology
researchProduct

Prognostic value of troponin I in atrial fibrillation

2021

To evaluate whether circulating cardiac troponin I (cTnI) levels are associated with worst outcomes in patients with atrial fibrillation (AF).Consecutive patients visiting the emergency room (ER) with a new episode of a previously diagnosed AF or a new diagnosis of AF during ER admission between January 1st, 2010 and December 31st, 2015, were enrolled in the study (n = 2617). After applying exclusion criteria and eliminating repeated episodes, 2013 patients were finally included. Of these, 1080 patients with at least one cTnI measurement in the ER were selected and classified into 4 groups according to cTnI quartiles: Q1 (n = 147) cTnI10 ng/L (Group 1); Q2 (n = 254): 10-19 ng/L (Group 2); Q…

Malemedicine.medical_specialtyTime FactorsHeart failureComorbidity030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicineTroponin ImedicineClinical endpointAtrial fibrillation Emergency Heart failure Mortality TroponinsTroponinsHumans030212 general & internal medicineRisk factorMortalityAdverse effectAgedRetrospective StudiesAged 80 and overbiologybusiness.industryTroponin IAtrial fibrillationMiddle AgedPrognosismedicine.diseaseTroponinAtrial fibrillationQuartileHeart failureEmergencybiology.proteinFemaleEmergency Service HospitalCardiology and Cardiovascular MedicinebusinessBiomarkers
researchProduct

Finding atrial fibrillation in stroke patients: Randomized evaluation of enhanced and prolonged Holter monitoring—Find-AFRANDOMISED —rationale and de…

2014

Background Detecting paroxysmal atrial fibrillation (AF) in patients with ischemic strokes presenting in sinus rhythm is challenging because episodes are often short, occur randomly, and are frequently asymptomatic. If AF is detected, recurrent thromboembolism can be prevented efficiently by oral anticoagulation. Numerous uncontrolled studies using various electrocardiogram (ECG) devices have established that prolonged ECG monitoring increases the yield of AF detection, but most established procedures are time-consuming and costly. The few randomized trials are mostly limited to cryptogenic strokes. The optimal method, duration, and patient selection remain unclear. Repeated prolonged conti…

Malemedicine.medical_specialtyTime FactorsPopulationAsymptomaticlaw.inventionRandomized controlled triallawGermanyInternal medicineMulticenter trialAtrial FibrillationPrevalencemedicineHumansSinus rhythmProspective Studiescardiovascular diseaseseducationStrokeAgededucation.field_of_studymedicine.diagnostic_testbusiness.industryIncidenceAtrial fibrillationmedicine.diseaseMagnetic Resonance Imaging3. Good healthSurgeryStrokeElectrocardiography AmbulatoryCardiologyFemalemedicine.symptomTomography X-Ray ComputedCardiology and Cardiovascular MedicinebusinessElectrocardiographyFollow-Up StudiesAmerican Heart Journal
researchProduct

Relationship between HRV measurements and demographic and clinical variables in a population of patients with atrial fibrillation.

2015

Little is known about the role of HRV in atrial fibrillation (AF) patients. Aim of our study was to assess the relationship between HRV measurements and demographic and clinical variables in a population of 274 AF patients. We selected all consecutive patients with persistent/permanent AF among whom had performed a Holter ECG in our Department from April 2010 to April 2015. Time-domain analysis of HRV was evaluated. Demographic and clinical variables were collected for each patient. At multivariable logistic regression, a higher pNN50 was associated with ACE inhibitors/ARBs (p = 0.016) and a lower pNN50 with obesity (p = 0.037) and higher heart rate (HR) (p < 0.0005). A higher RMSSD w…

Malemedicine.medical_specialtyTime FactorsPopulationDigitalisComorbidity030204 cardiovascular system & hematologyAutonomic Nervous System03 medical and health sciences0302 clinical medicineHeart RateRisk FactorsInternal medicineHeart rateAtrial FibrillationmedicineHeart rate variabilityHumansSinus rhythm030212 general & internal medicineeducationStrokeHeart rate variabilityAgedRetrospective StudiesAged 80 and overeducation.field_of_studybiologybusiness.industryAtrial fibrillationHeartmedicine.diseasebiology.organism_classificationCardiac surgeryAntiarrhythmic drugCross-Sectional StudiesLogistic ModelsItalyMultivariate AnalysisCardiologyElectrocardiography AmbulatoryLinear ModelsPolypharmacyFemalebusinessCardiology and Cardiovascular MedicineAnti-Arrhythmia AgentsHolter ECGHeart and vessels
researchProduct

Impact of Midregional N‐Terminal Pro–Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treate…

2021

Background We assessed the impact of preprocedural plasma levels of MRproANP (midregional N‐terminal pro–atrial natriuretic peptide) and sST2 (soluble suppression of tumorigenicity 2) on recurrence of atrial fibrillation (AF) at 1 year after catheter ablation of AF. Methods and Results This was a prospective, multicenter, observational study including patients undergoing catheter ablation of AF. MRproANP and sST2 were measured in a peripheral venous blood preprocedure, and MRproANP was assessed in the right and left atrial blood during ablation. The primary end point was recurrent AF between 3 and 12 months postablation, defined as a documented (&gt;30 seconds) episode of AF, flutter, or a…

Malemedicine.medical_specialtyTime Factorsmedicine.drug_classmedicine.medical_treatmentBiorhythmCatheter ablation030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineHeart RatePredictive Value of TestsRecurrenceRisk FactorsInternal medicinecatheter ablationAtrial FibrillationmedicineNatriuretic peptideHumansIn patientArrhythmia and Electrophysiology030212 general & internal medicineHeart AtriaProspective StudiesOriginal ResearchAgedsST2business.industryMRproANPbiomarkersAtrial fibrillationPlasma levelsMiddle Agedmedicine.diseaseInterleukin-1 Receptor-Like 1 ProteinUp-RegulationHeart RhythmTreatment OutcomePro atrial natriuretic peptideCardiologyFemaleFranceCardiology and Cardiovascular MedicinebusinessCatheter Ablation and Implantable Cardioverter-DefibrillatorAtrial Natriuretic FactorJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
researchProduct

Impact of biatrial defragmentation in patients with paroxysmal atrial fibrillation: Results from a randomized prospective study

2014

Single procedure success rates of pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation (PAF) are still unsatisfactory. In patients with persistent atrial fibrillation (AF), ablation of complex fractionated atrial electrograms (CFAEs) after PVI results in improved outcomes.We aimed to investigate if PAF-patients with intraprocedurally sustained AF after PVI might benefit from additional CFAE ablation.A total of 1134 consecutive patients underwent a first catheter ablation procedure of PAF between June 2008 and December 2012. In most patients, AF was either not inducible or terminated during PVI. In 68 patients (6%), AF sustained after successful PVI. These patients …

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentElectric CountershockCatheter ablationCardioversionPulmonary veinHeart Conduction SystemHeart RatePhysiology (medical)Internal medicineAtrial FibrillationmedicineHumansSinus rhythmProspective StudiesTachycardia ParoxysmalProspective cohort studyAtrial tachycardiabusiness.industryAtrial fibrillationMiddle Agedmedicine.diseaseAblationTreatment OutcomePulmonary VeinsAnesthesiaCatheter AblationCardiologyFemalemedicine.symptomElectrophysiologic Techniques CardiacCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesHeart Rhythm
researchProduct

Mortality after cardioverter-defibrillator replacement: Results of the DECODE survival score index

2020

Background Device replacement is the ideal time to reassess health care goals regarding continuing implantable cardioverter-defibrillator (ICD) therapy. Only few data are available on the decision making at this time. Objectives The goals of this study were to identify factors associated with poor prognosis at the time of ICD replacement and to develop a prognostic index able to stratify those patients at risk of dying early. Methods DEtect long-term COmplications after implantable cardioverter-DEfibrillator replacement (DECODE) was a prospective, single-arm, multicenter cohort study aimed at estimating long-term complications in a large population of patients who underwent ICD/cardiac resy…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulationReplacementCardiac resynchronization therapy030204 cardiovascular system & hematologyPrognostic indexImplantable cardioverter-defibrillatorNOElectrocardiography03 medical and health sciences0302 clinical medicineInterquartile rangePhysiology (medical)Internal medicinemedicineHumansProspective Studies030212 general & internal medicineeducationShared decision makingAgedOutcomeAged 80 and overHeart Failureeducation.field_of_studyIschemic cardiomyopathybusiness.industryProportional hazards modelMiddle AgedImplantable cardioverter-defibrillatorDefibrillators ImplantableSurvival RateDeath Sudden CardiacItalyFemaleCardiology and Cardiovascular MedicinebusinessDecision Making SharedBody mass indexFollow-Up StudiesCohort study
researchProduct

Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national…

2021

Abstract Aims Vitamin K antagonists (VKAs) are effective drugs reducing the risk for stroke in atrial fibrillation (AF), but the benefits derived from such therapy depend on the international normalized ratio (INR) maintenance in a narrow therapeutic range. Here, we aimed to determine independent variables driving poor anticoagulation control [defined as a time in therapeutic range (TTR) &amp;lt;65%] in a ‘real world’ national cohort of AF patients. Methods and results The SULTAN registry is a multicentre, prospective study, involving patients with non-valvular AF from 72 cardiology units expert in AF in Spain. At inclusion, all patients naïve for oral anticoagulation were started with VKAs…

Malemedicine.medical_specialtyVitamin K030204 cardiovascular system & hematologyAmiodaroneCoronary artery disease03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineAtrial FibrillationHumansMedicineInternational Normalized RatioProspective StudiesRegistries030212 general & internal medicineProspective cohort studyStrokeAgedAged 80 and overbusiness.industryProportional hazards modelAnticoagulantsAtrial fibrillationOdds ratioMiddle Agedmedicine.diseaseConfidence intervalStrokeFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEP Europace
researchProduct